Supplemental Preliminary Amendment Application No. 09/763.213 Attorney's Docket No. 001560-390 Page 3

REMARKS

As required by the new rules and procedures for filing Amendments, applicants are filing this Supplemental Preliminary Amendment to submit a marked-up copy and clean set of claims. It is respectfully submitted that no new matter is presented by the above amendments.

In the previous Preliminary Amendment, filed February 20, 2001, claims 7-10 were deleted and new claims 14-24 were added. These amendments should be entered in the application as set forth in the previous Preliminary Amendment. No revisions to these aspects of the amendment are necessary due to the new rules and procedures.

No further amendments are being requested at this time.

Favorable action in the form of a Notice of Allowance is respectfully requested.

The Commissioner of Patents is hereby authorized to charge any necessary fees, or credit any overpayment to the undersigned's deposit account no. 02-4800.

Supplemental Preliminary Amendment Application No. <u>09/763.213</u> Attorney's Docket No. <u>001560-390</u> Page 4

In the event that there are any questions relating to this amendment, or to the application in general, it would be appreciated if the Examiner would telephone the undersigned attorney at 508-339-3684 concerning such questions so that prosecution of this application may be expedited.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Donna M. Meuth

Registration No. 36,607

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: May 30, 2001

CERTIFICATE OF FACSIMILE TRANSMITTAL

I hereby certify that this Supplemental Preliminary Amendment is being filed in the U.S. Patent and Trademark Office, together with the attached set of marked-up claims, on the date shown below.

Amy Scipione

5/30/0/ Date



Application No. 09/763,213 Attorney Docket No. 001560-390 Page 1

Attachment to Supplemental Preliminary Amendment dated May 30, 2001 Marked-up Claims 3-6

- 3. (Amended) A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 1 [or 2], wherein, in the formula (1), R² is a carboxylic acid group or a hydrogen atom.
- 4. (Amended) A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in [any one of claims 1 to 3] claim 1, wherein R³ in the formula (I) is a hydrogen atom.
- 5. (Amended) A pharmaceutical composition comprising as an effective ingredient a pharmaceutically effective amount of a quinazoline derivative or the pharmaceutically acceptable salt thereof according to [any one of claims 1 to 4] claim 1 and a pharmaceutically acceptable carrier therefor.
- 6. (Amended) A chymase inhibitor having as an effective ingredient a quinazoline derivative or its pharmaceutically salt according to [any one of claims 1 to 4] claim 1.

(10/00)